Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association

Carmel Bogle, Steven D. Colan, Shelley D. Miyamoto, Swati Choudhry, Nathanya Baez-Hernandez, Molly M. Brickler, Brian Feingold, Ashwin K. Lal, Teresa M. Lee, Charles E. Canter, Steven E. Lipshultz

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

This scientific statement from the American Heart Association focuses on treatment strategies and modalities for cardiomyopathy (heart muscle disease) in children and serves as a companion scientific statement for the recent statement on the classification and diagnosis of cardiomyopathy in children. We propose that the foundation of treatment of pediatric cardiomyopathies is based on these principles applied as personalized therapy for children with cardiomyopathy: (1) identification of the specific cardiac pathophysiology; (2) determination of the root cause of the cardiomyopathy so that, if applicable, cause-specific treatment can occur (precision medicine); and (3) application of therapies based on the associated clinical milieu of the patient. These clinical milieus include patients at risk for developing cardiomyopathy (cardiomyopathy phenotype negative), asymptomatic patients with cardiomyopathy (phenotype positive), patients with symptomatic cardiomyopathy, and patients with end-stage cardiomyopathy. This scientific statement focuses primarily on the most frequent phenotypes, dilated and hypertrophic, that occur in children. Other less frequent cardiomyopathies, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic cardiomyopathy, are discussed in less detail. Suggestions are based on previous clinical and investigational experience, extrapolating therapies for cardiomyopathies in adults to children and noting the problems and challenges that have arisen in this experience. These likely underscore the increasingly apparent differences in pathogenesis and even pathophysiology in childhood cardiomyopathies compared with adult disease. These differences will likely affect the utility of some adult therapy strategies. Therefore, special emphasis has been placed on cause-specific therapies in children for prevention and attenuation of their cardiomyopathy in addition to symptomatic treatments. Current investigational strategies and treatments not in wide clinical practice, including future direction for investigational management strategies, trial designs, and collaborative networks, are also discussed because they have the potential to further refine and improve the health and outcomes of children with cardiomyopathy in the future.

Original languageEnglish
Pages (from-to)174-195
Number of pages22
JournalCirculation
Volume148
Issue number2
DOIs
StatePublished - Jul 11 2023

Keywords

  • AHA Scientific Statements
  • cardiomyopathies
  • child
  • heart diseases
  • precision medicine

Fingerprint

Dive into the research topics of 'Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association'. Together they form a unique fingerprint.

Cite this